Page last updated: 2024-10-28

hydralazine and Cardiotoxicity

hydralazine has been researched along with Cardiotoxicity in 1 studies

Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.

Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mozolevska, V1
Schwartz, A1
Cheung, D1
Goyal, V1
Shaikh, B1
Dingman, B1
Kim, E1
Mittal, I1
Asselin, CY1
Edel, A1
Ravandi, A1
Thliveris, J1
Singal, PK1
Czaykowski, P1
Jassal, DS1

Other Studies

1 other study available for hydralazine and Cardiotoxicity

ArticleYear
Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
    American journal of physiology. Heart and circulatory physiology, 2019, 03-01, Volume: 316, Issue:3

    Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antineoplastic Ag

2019